SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
NCT ID: NCT03645876
Last Updated: 2019-05-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
12 participants
INTERVENTIONAL
2018-11-08
2019-04-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
SHR-1210 is a humanized monoclonal antibody against Programmed death 1(PD-1).BP102 is a humanized recombinant monoclonal IgG1 antibody.
The primary objective of this study is to investigate the safety and efficacy of the subjects who given the combination therapy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC
NCT04856787
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
NCT01767857
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
NCT07071714
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
NCT05799820
SHR-1701 Combined with SHR2554 and BP102 for MCRC
NCT06679673
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SHR-1210+BP102+XELOX
Participants receive SHR-1210 200mg,BP102 7.5mg/kg and oxaliplatin 130mg/m2 in day 1 intravenously every 3week, capecitabine by oral bid in day1-14 every 3 week until disease progression or unacceptable toxicity
SHR-1210
200mg
BP102
7.5mg/kg
oxaliplatin
130mg/m2
capecitabine
1000mg/m2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SHR-1210
200mg
BP102
7.5mg/kg
oxaliplatin
130mg/m2
capecitabine
1000mg/m2
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Histologically confirmed colorectal cancer with a metastatic / recurrent lesion that cannot be cured by surgery.
3. At least one measurable lesion have been the confirmatory detection respect to RECIST 1.1
4. No prior first-line systemic anti-tumor therapy for mCRC (including systemic chemotherapy, molecular targeted therapy, biotherapy, immunotherapy, radiotherapy, local therapy and other study treatment) have been identified
5. At least 6 months have elapsed if considering the interval from the time of firstly documented metastasis to the post-operational adjuvant chemotherapy termination
6. Can provide either a newly obtained or archival tumor tissue sample.
7. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
8. Life expectancy ≥ 3 months
9. Subjects must have normal organ and marrow function as defined below:
1. Absolute neutrophil count (ANC) ≥1,500 /mm3(1.5×109 /L)
2. Platelets ≥90,000 / mm3(90×109 /L)
3. Hemoglobin ≥10 g/dL, within the 2 weeks prior to the screening no need for the transfusion
4. Serum albumin ≥2.8 g/dL
5. Total bilirubin≤ 1.5 X ULN, AST (SGOT), ALT (SGPT) ≤ 2.5 X ULN (AST/ALT ≤ 5 X ULN if liver metastatic);
6. Creatinine clearance ≥ 50 mL/min according to Cockcroft-Gault formula
10. For females of child bearing potential, a negative urine or serum pregnancy test result within 72h before study treatment. Participants of reproductive potential must be willing to use adequate contraception for the course of the study until 3 months after the last dose of any of the drugs in the study.
11. The subjects are accredited with good compliance, signed the informed consent, and capable to cooperate, completing the relevant examination and follow-ups.
Exclusion Criteria
2. The metastatic/recurrent lesion is subject to be cured by surgical intervention.
3. Major operation or open biopsy or major trauma within 4 weeks prior to first dose.
4. Known Cerebral and/or leptomeningeal metastasis.
5. Bleeding predisposition, high bleeding risk or coagulant disorder, thrombotic event(s) occurrence ≤6 months and/or hemoptysis ≤3 months (≥ 1/2 teaspoons fresh blood each) prior to the screening; use of full dose oral or parenteral anticoagulant or thrombolytic medication (allowing preventative anticoagulation); use of aspirin (\> 325 mg/day) or other platelet-inhibition non-steroidal anti-inflammatory drugs within 10 days since the screening; CT/MRI imaging evidence, testimony of the main arteries/veins (such as pulmonary artery or superior vena cava) being infringed, encroached
6. Subjects with uncontrolled hypertension and with a medical history of hypertensive crisis or hypertensive encephalopathy; serious cardiovascular and cerebrovascular diseases, including cerebrovascular accident (CVA) ≤6 months before the screening, transient ischemic attack (TIA), myocardial infarction and significant vascular disease (including but not limited to aortic aneurysms with need for surgical repair or recent evidence of arterial thrombosis), unstable angina, heart failure and serious arrhythmias that are uncontrolled by drugs (New York Heart Association Class ≥2).
7. Subjects with non-healing wounds, active peptic ulcer or fracture and active infection; tracheal esophageal fistula, gastrointestinal perforation or gastrointestinal fistula and abdominal abscess in the 6 months prior to the screening.
8. Subjects with any active autoimmune disease or history of autoimmune disease
9. Active infection or an unexplained fever \> 38.5°C before two weeks of randomization (subjects with tumor fever may be enrolled at the discretion of the investigator);
10. History of Interstitial Pneumonia or received Corticosteroids for non-infectious pneumonitis.
11. Known Human Immunodeficiency Virus (HIV) infection、active Hepatitis B or Hepatitis C.
12. Known history of hypersensitivity to macromolecular protein preparation or any components of the SHR-1210 or BP102 formulation, allergy, hypersensitivity, or contraindication to oxaliplatin, or Capecitabine
13. Currently participating or has participated in a study within 4 weeks of the first dose of study medication.
14. Has a known additional malignancy within the last 5 years before study treatment with the exception of curatively treated basal cell and squamous cell carcinoma of the skin and/or curatively resected in-situ cervical and/or breast cancers
15. Received a live vaccine within 4 weeks of the first dose of study medication
16. Pregnancy or breast feeding.
17. According to the investigator, other conditions that may lead to stop the research.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jiangsu HengRui Medicine Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cancer Center of Sun-Yat Sen University (CCSYSU)
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHR-1210-II-210
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.